blood cancer

September 24, 2020

VICC leading first global study of MDS/MPN overlap syndrome

Overlap syndromes are distinct blood cancers that present with features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

By Tom Wilemon
July 23, 2020

Cellular antiviral defenses

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.

By Leigh MacMillan
red and blue boxing gloves
March 5, 2020

One-two punch for cancer

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

By Sanjay Mishra
Dona Potter was treated with a new immunotherapy that entails re-engineering a patient’s T cells to target cancer.
February 27, 2020

Patient’s cancer treatment includes new immunotherapy

Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.

By Tom Wilemon
August 1, 2019

Grant bolsters research on myelodysplastic syndromes

Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes.

By Tom Wilemon
April 19, 2019

Doctor and patient compete for honor

By Tom Wilemon
January 31, 2019

Cell death pathway implicated in bone marrow failure

Vanderbilt investigators have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.
By Leigh MacMillan
August 2, 2018

Connecting an asthma gene to leukemia

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.
By Leigh MacMillan
October 25, 2017

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.
By VUMC News and Communications
September 18, 2017

New cutting-edge treatment for type of pediatric leukemia offered at Monroe Carell Jr. Children’s Hospital at Vanderbilt 

By Christina Echegaray
August 3, 2017

HDAC3 role in B-cell development

The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.
By Leigh MacMillan
September 14, 2016

Restore T cells to fight leukemia

Modulation of T cell metabolism thus may represent a new therapeutic avenue for leukemia patients.
By Bill Snyder
March 3, 2016

First VICC cancer patient treated with new immunotherapy

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.
By VUMC News and Communications
1 2 3 4